Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study)

Antoine Yrondi 1 Bruno Aouizerate 2, 3 Wissam El-Hage 4, 5 Fanny Moliere 6, 7 Claire Thalamas 8 Nicolas Delcourt 1 Marie Sporer 9 Simon Taib 9 Laurent Schmitt 9 Nicolas Arlicot 4, 5 Deborah Meligne 10 Agnés Sommet 8 Anne Salabert 1 Sébastien Guillaume 6, 7, 11 Philippe Courtet 6, 7, 11 Florence Galtier 6, 12 Denis Mariano-Goulart 6, 13 Nicolas Menjot de Champfleur 14, 15, 16, 17 Emmanuel Bars 14, 15 Thomas Desmidt 4 Mathieu Lemaire 4 Vincent Camus 4 Maria Santiago-Ribeiro 4, 5 Jean Cottier 4, 18 Philippe Fernandez 19, 20 Marie Meyer 19, 20 Vincent Dousset 21, 22 Olivier Doumy 2, 3 Didier Delhaye 2 Lucile Capuron 3 Marion Leboyer 23, 24, 25 Emmanuel Haffen 7, 26, 27 Patrice Péran 1 Pierre Payoux 1 Christophe Arbus 1
Abstract : Background: Major depressive disorder (MDD) is a serious public health problem with high lifetime prevalence (4.4-20%) in the general population. The monoamine hypothesis is the most widespread etiological theory of MDD. Also, recent scientific data has emphasized the importance of immuno-inflammatory pathways in the pathophysiology of MDD. The lack of data on the magnitude of brain neuroinflammation in MDD is the main limitation of this inflammatory hypothesis. Our team has previously demonstrated the relevance of [18F] DPA-714 as a neuroinflammation biomarker in humans. We formulated the following hypotheses for the current study: (i) Neuroinflammation in MDD can be measured by [18F] DPA-714; (ii) its levels are associated with clinical severity; (iii) it is accompanied by anatomical and functional alterations within the frontal-subcortical circuits; (iv) it is a marker of treatment resistance. Methods: Depressed patients will be recruited throughout 4 centers (Bordeaux, Montpellier, Tours, and Toulouse) of the French network from 13 expert centers for resistant depression. The patient population will be divided into 3 groups: (i) experimental group-patients with current MDD (n = 20), (ii) remitted depressed group-patients in remission but still being treated (n = 20); and, (iii) control group without any history of MDD (n = 20). The primary objective will be to compare PET data (i.e., distribution pattern of neuroinflammation) between the currently depressed group and the control group. Secondary objectives will be to: (i) compare neuroinflammation across groups (currently depressed group vs. remitted depressed group vs. control group); (ii) correlate neuroinflammation with clinical severity across groups; (iii) correlate neuroinflammation with MRI parameters for structural and functional integrity across groups; (iv) correlate neuroinflammation and peripheral markers of inflammation across groups. Discussion: This study will assess the effects of antidepressants on neuroinflammation as well as its role in the treatment response. It will contribute to clarify the putative relationships between neuroinflammation quantified by brain neuroimaging techniques and peripheral markers of inflammation. Lastly, it is expected to open innovative and promising therapeutic perspectives based on anti-inflammatory strategies for the management of treatment-resistant forms of MDD commonly seen in clinical practice. Clinical trial registration (reference: NCT03314155): https://www.clinicaltrials.gov/ct2/show/NCT03314155?term=neuroinflammation&cond=depression&cntry=FR&rank=1.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-01856019
Contributeur : Dominique Mornet <>
Soumis le : lundi 30 mars 2020 - 16:15:28
Dernière modification le : mardi 27 octobre 2020 - 14:34:46

Fichier

2018 Yrondi et al., Assessmen...
Fichiers produits par l'(les) auteur(s)

Licence


Distributed under a Creative Commons Paternité 4.0 International License

Identifiants

Citation

Antoine Yrondi, Bruno Aouizerate, Wissam El-Hage, Fanny Moliere, Claire Thalamas, et al.. Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study). Frontiers in Psychiatry, Frontiers, 2018, 9, pp.326. ⟨10.3389/fpsyt.2018.00326⟩. ⟨hal-01856019⟩

Partager

Métriques

Consultations de la notice

587

Téléchargements de fichiers

264